Daniel P Normolle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1761076/publications.pdf

Version: 2024-02-01

120 papers 11,246 citations

51 h-index 104 g-index

120 all docs

120 docs citations 120 times ranked 14998 citing authors

#	Article	IF	CITATIONS
1	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. Cancer Immunology Research, 2022, 10, 885-899.	1.6	7
2	Adaptive Phase 1 Design in Radiation Therapy Trials. International Journal of Radiation Oncology Biology Physics, 2022, 113 , 493 - 499 .	0.4	1
3	Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1639-1648.e2.	0.4	37
4	Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. Oncology Research, 2021, 28, 811-814.	0.6	3
5	A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy. Supportive Care in Cancer, 2021, , 1.	1.0	5
6	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Science Immunology, 2020, 5, .	5.6	36
7	An Adaptive Bayesian Design for Personalized Dosing in a Cancer Prevention Trial. American Journal of Preventive Medicine, 2020, 59, e167-e173.	1.6	1
8	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
9	The Rad51 paralogs facilitate a novel DNA strand specific damage tolerance pathway. Nature Communications, 2019, 10, 3515.	5.8	26
10	Current good manufacturing practices–compliant manufacture and measurement of biotin-labeled red blood cells. Cytotherapy, 2019, 21, 793-800.	0.3	5
11	Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Nonâ€"Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. Journal of Clinical Oncology, 2019, 37, 1316-1325.	0.8	336
12	A phase 2 trial of regorafenib as a single agent in patients with chemotherapyâ€refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer, 2019, 125, 902-909.	2.0	98
13	Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer, 2019, 128, 145-151.	0.9	32
14	A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2595-2601.	0.6	10
15	Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prevention Research, 2018, 11, 337-346.	0.7	15
16	Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 326-331.	0.6	1
17	Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage. JAMA Oncology, 2018, 4, 40.	3.4	140
18	Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma. Pancreas, 2018, 47, 856-863.	0.5	38

#	Article	IF	CITATIONS
19	Interferon-Î ³ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell, 2017, 169, 1130-1141.e11.	13.5	431
20	The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity. Cancer Prevention Research, 2017, 10, 729-737.	0.7	16
21	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. Neuro-Oncology, 2017, 19, vi28-vi28.	0.6	0
22	Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfusion and Apheresis Science, 2016, 55, 216-220.	0.5	23
23	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Journal of Neuro-Oncology, 2016, 130, 517-527.	1.4	49
24	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research, 2016, 9, 547-557.	0.7	77
25	Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 305-311.	0.4	18
26	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro-Oncology, 2016, 18, 1157-1168.	0.6	69
27	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	0.7	187
28	Macrophages and Myeloid Dendritic Cells Lose T Cell–Stimulating Function in Simian Immunodeficiency Virus Infection Associated with Diminished IL-12 and IFN-α Production. Journal of Immunology, 2015, 195, 3284-3292.	0.4	26
29	VDR Activity Is Differentially Affected by Hic-5 in Prostate Cancer and Stromal Cells. Molecular Cancer Research, 2014, 12, 1166-1180.	1.5	17
30	Neuroplastic Changes Occur Early in the Development of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2014, 74, 1718-1727.	0.4	140
31	Biomarkers for Personalizing Omega-3 Fatty Acid Dosing. Cancer Prevention Research, 2014, 7, 1011-1022.	0.7	16
32	Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio. Translational Oncology, 2014, 7, 479-483.	1.7	7
33	Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non–Small-Cell Lung Cancer: A Propensity-Matched Analysis. Journal of Clinical Oncology, 2014, 32, 2449-2455.	0.8	227
34	Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiation Oncology, 2013, 8, 204.	1.2	14
35	Prediction of Liver Function by Using Magnetic Resonance-based Portal Venous Perfusion Imaging. International Journal of Radiation Oncology Biology Physics, 2013, 85, 258-263.	0.4	60
36	Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. Leukemia and Lymphoma, 2013, 54, 1965-1974.	0.6	3

#	Article	IF	CITATIONS
37	Statistical classification of multivariate flow cytometry data analyzed by manual gating: Stem, progenitor, and epithelial marker expression in nonsmall cell lung cancer and normal lung. , 2013, 83A, 150-160.		8
38	Fineâ€needle aspiration of gray zone lesions of the breast: Fibroadenoma versus ductal carcinoma. Diagnostic Cytopathology, 2013, 41, 806-811.	0.5	6
39	Blocking TLR7- and TLR9-mediated IFN-α Production by Plasmacytoid Dendritic Cells Does Not Diminish Immune Activation in Early SIV Infection. PLoS Pathogens, 2013, 9, e1003530.	2.1	53
40	Response of Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Xenografts to a Survivin Inhibitor. PLoS ONE, 2013, 8, e80543.	1.1	38
41	Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2012, 18, 273-279.	3.2	115
42	Alcohol and Tobacco Lower the Age of Presentation in Sporadic Pancreatic Cancer in a Dose-Dependent Manner: A Multicenter Study. American Journal of Gastroenterology, 2012, 107, 1730-1739.	0.2	55
43	NF-l ^o B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells. Cancer Research, 2012, 72, 3735-3743.	0.4	119
44	Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood, 2012, 119, 4608-4613.	0.6	111
45	Survivin Is a Therapeutic Target in Merkel Cell Carcinoma. Science Translational Medicine, 2012, 4, 133ra56.	5.8	117
46	A Phase I Clinical and Pharmacology Study Using Amifostine as a Radioprotector in Dose-escalated Whole Liver Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1441-1447.	0.4	39
47	Dosimetric Analysis of Radiation-induced Gastric Bleeding. International Journal of Radiation Oncology Biology Physics, 2012, 84, e1-e6.	0.4	18
48	A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1166-1171.	0.4	174
49	How Much Pharyngeal Exposure Is "Normal� Normative Data for Laryngopharyngeal Reflux Events Using Hypopharyngeal Multichannel Intraluminal Impedance (HMII). Journal of Gastrointestinal Surgery, 2012, 16, 16-25.	0.9	137
50	Molecular Imaging of Akt Enables Early Prediction of Response to Molecular Targeted Therapy. Translational Oncology, 2011, 4, 122-IN1.	1.7	7
51	Rectal mucosal quantitative galactose oxidase-Schiff reaction as an early detection biomarker for colorectal cancer: Comparison to fecal occult stool blood test. Cancer Biomarkers, 2011, 8, 109-112.	0.8	1
52	Phase II Study of the Effects of Ginger Root Extract on Eicosanoids in Colon Mucosa in People at Normal Risk for Colorectal Cancer. Cancer Prevention Research, 2011, 4, 1929-1937.	0.7	43
53	Bayesian Hierarchical Changepoint Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments. Clinical Cancer Research, 2011, 17, 1057-1064.	3.2	28
54	Modeling the Tumor Growth Profiles in Xenograft Experiments—Response. Clinical Cancer Research, 2011, 17, 4613-4613.	3.2	0

#	Article	IF	Citations
55	Chemopreventative Potential of the Cruciferous Vegetable Constituent Phenethyl Isothiocyanate in a Mouse Model of Prostate Cancer. Journal of the National Cancer Institute, 2011, 103, 571-584.	3.0	94
56	A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,. Blood, 2011, 118, 4142-4142.	0.6	3
57	Phenethyl Isothiocyanate Inhibits Oxidative Phosphorylation to Trigger Reactive Oxygen Species-mediated Death of Human Prostate Cancer Cells. Journal of Biological Chemistry, 2010, 285, 26558-26569.	1.6	158
58	Mechanism of Radiosensitization by the Chk $1/2$ Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair. Cancer Research, 2010, 70, 4972-4981.	0.4	267
59	Sensitivity of Quantitative Metrics Derived from DCE MRI and a Pharmacokinetic Model to Image Quality and Acquisition Parameters. Academic Radiology, 2010, 17, 468-478.	1.3	41
60	Adaptive trial of personalized radiotherapy for intrahepatic cancer. Personalized Medicine, 2010, 7, 197-204.	0.8	16
61	Prechemotherapy alterations in brain function in women with breast cancer. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 324-331.	0.8	141
62	Quantitation of 6-, 8- and 10-Gingerols and 6-Shogaol in Human Plasma by High-Performance Liquid Chromatography with Electrochemical Detection. International Journal of Biomedical Science, 2010, 6, 233-240.	0.5	26
63	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction. Clinical Cancer Research, 2009, 15, 1747-1754.	3.2	59
64	Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Supportive Care in Cancer, 2009, 17, 563-572.	1.0	144
65	Characterization of Pancreatic Tumor Motion Using Cine MRI: Surrogates for Tumor Position Should Be Used With Caution. International Journal of Radiation Oncology Biology Physics, 2009, 74, 884-891.	0.4	159
66	\hat{l}_{\pm} -Fetoprotein, Des- \hat{l}^3 Carboxyprothrombin, and Lectin-Bound \hat{l}_{\pm} -Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2009, 137, 110-118.	0.6	644
67	Hepatic absorbed radiation dosimetry during I-131 Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2105-2112.	3.3	16
68	Liver Function After Irradiation Based on Computed Tomographic Portal Vein Perfusion Imaging. International Journal of Radiation Oncology Biology Physics, 2008, 70, 154-160.	0.4	47
69	Pharmacokinetics of 6-Gingerol, 8-Gingerol, 10-Gingerol, and 6-Shogaol and Conjugate Metabolites in Healthy Human Subjects. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1930-1936.	1.1	239
70	Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1411-1417.	1.1	435
71	Chromoendoscopy Detects More Adenomas than Colonoscopy Using Intensive Inspection without Dye Spraying. Cancer Prevention Research, 2008, 1, 507-513.	0.7	48
72	SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis, 2008, 29, 858-865.	1.3	33

#	Article	IF	CITATIONS
73	Missed Adenomas during Colonoscopic Surveillance in Individuals with Lynch Syndrome (Hereditary) Tj ETQq1 1	0.784314	rgBT /Over
74	The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 5142-5149.	3.2	113
75	A Pilot Study of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 3116-3123.	0.8	154
76	Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo. Clinical Cancer Research, 2007, 13, 2512-2518.	3.2	48
77	SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and lîºB-α/NF-κB. Journal of Cell Biology, 2007, 178, 1009-1023.	2.3	51
78	Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 4587-4592.	0.8	51
79	Biomarkers for Cancer Risk, Early Detection, and Prognosis: The Validation Conundrum. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1918-1920.	1.1	44
80	The prediction of radiation-induced liver dysfunction using a local dose and regional venous perfusion model. Medical Physics, 2007, 34, 604-612.	1.6	34
81	Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer. Head and Neck, 2007, 29, 137-142.	0.9	28
82	Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 182-187.	1.2	173
83	Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine, 2006, 6, 10.	3.7	1,034
84	Designing Dose-Escalation Trials With Late-Onset Toxicities Using the Time-to-Event Continual Reassessment Method. Journal of Clinical Oncology, 2006, 24, 4426-4433.	0.8	95
85	Combination Tetrathiomolybdate and Radiation Therapy in a Mouse Model of Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2006, 132, 333.	1.5	13
86	Body Mass Index Predicts the Incidence of Radiation Pneumonitis in Breast Cancer Patients. Cancer Journal (Sudbury, Mass), 2005, 11, 390-398.	1.0	15
87	Testing new chemoradiation regimens for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 5-6.	0.4	5
88	Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1325-1330.	0.4	41
89	Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies. Journal of Clinical Oncology, 2005, 23, 8739-8747.	0.8	308
90	Challenges in herbal research: A randomized clinical trial to assess blinding with ginger. Complementary Therapies in Medicine, 2005, 13, 101-106.	1.3	15

#	Article	IF	CITATIONS
91	Design of early validation trials of biomarkers. Cancer Informatics, 2005, 1, 25-31.	0.9	2
92	Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2004, 22, 238-243.	0.8	95
93	Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. Cancer Detection and Prevention, 2004, 28, 107-113.	2.1	3
94	Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1461-1467.	0.4	54
95	Dysplasia in Barrett esophagus. Cancer, 2004, 100, 1622-1627.	2.0	18
96	Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal Radiotherapy. Journal of Clinical Oncology, 2002, 20, 1635-1642.	0.8	353
97	Postmastectomy radiotherapy of the chest wall: dosimetric comparison of common techniques. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1220-1230.	0.4	148
98	Analysis of radiation-induced liver disease using the Lyman NTCP model. International Journal of Radiation Oncology Biology Physics, 2002, 53, 810-821.	0.4	688
99	Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2001, 19, 4202-4208.	0.8	300
100	Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). International Journal of Radiation Oncology Biology Physics, 2000, 47, 785-791.	0.4	72
101	Escalated Focal Liver Radiation and Concurrent Hepatic Artery Fluorodeoxyuridine for Unresectable Intrahepatic Malignancies. Journal of Clinical Oncology, 2000, 18, 2210-2218.	0.8	362
102	Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor. Human Gene Therapy, 2000, 11, 839-850.	1.4	70
103	Association of the Prothrombin G20210A Mutation With Factor V Leiden in a Midwestern American Population. American Journal of Clinical Pathology, 2000, 114, 272-275.	0.4	12
104	Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines. Clinical Immunology, 2000, 94, 64-72.	1.4	18
105	Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis, 1999, 20, 1985-1995.	1.3	135
106	3-D color Doppler image quantification of breast masses. Ultrasound in Medicine and Biology, 1998, 24, 945-952.	0.7	35
107	The multidisciplinary melanoma clinic: A cost outcomes analysis of specialty care. Journal of the American Academy of Dermatology, 1998, 38, 742-751.	0.6	63
108	The 3D and 2D color flow display of breast masses. Ultrasound in Medicine and Biology, 1997, 23, 837-849.	0.7	56

#	Article	IF	CITATIONS
109	Effect of Bromodeoxyuridine on Radiation-Induced DNA Damage and Repair Based on DNA Fragment Size Using Pulsed-Field Gel Electrophoresis. Radiation Research, 1995, 144, 282.	0.7	15
110	Use of fluorescence in situ hybridization (fish) to study chromosomal damage induced by radiation and bromodeoxyuridine in human colon cancer cells. International Journal of Radiation Oncology Biology Physics, 1994, 30, 861-866.	0.4	9
111	P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clinical Pharmacology and Therapeutics, 1994, 56, 253-260.	2.3	50
112	Identification of Aperiodic Seasonality in Non-Gaussian Time Series. Biometrics, 1994, 50, 798.	0.8	5
113	The use of biphasic linear ramped pulsed field gel electrophoresis to quantify dna damage based on fragment size distribution. International Journal of Radiation Oncology Biology Physics, 1993, 27, 659-663.	0.4	20
114	AN algorithm for robust non-linear analysis of radioimmunoassays and other bioassays. Statistics in Medicine, 1993, 12, 2025-2042.	0.8	18
115	Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clinical Pharmacology and Therapeutics, 1992, 52, 471-478.	2.3	61
116	Statistics and clinical trials: The case of prednisolone in alcoholic hepatitis. Hepatology, 1992, 16, 1098-1099.	3.6	0
117	Urodynamic tests for female geriatricurinary incontinence. Urology, 1990, 36, 431-439.	0.5	43
118	Prevalence and outcome of surgery for female incontinence. Urology, 1989, 33, 285-290.	0.5	14
119	Methods Used to Manage Urinary Incontinence by Older Adults in the Community. Journal of the American Geriatrics Society, 1989, 37, 339-347.	1.3	95
120	Clinical and Cystometric Characteristics of Continent and Incontinent Noninstitutionalized Elderly. Journal of Urology, 1988, 140, 567-571.	0.2	171